Your shopping cart is currently empty

PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | In Stock | In Stock | |
| 5 mg | $258 | In Stock | In Stock | |
| 10 mg | $382 | In Stock | In Stock | |
| 25 mg | $592 | In Stock | In Stock | |
| 50 mg | $816 | In Stock | In Stock | |
| 100 mg | $1,090 | In Stock | In Stock | |
| 200 mg | $1,480 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $398 | In Stock | In Stock |
| Description | PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2). |
| In vitro | In HMC-1 cells, PMX-53 (10 nM) inhibits C5a-induced Ca2+ mobilization, but at higher concentrations( ≥30 nM) it causes degranulation in LAD2 mast cells, CD34+ cell-derived mast cells, and RBL-2H3 cells stably expressing MrgX2. Replacement of Trp with Ala and Arg with dArg eliminates the ability of PMX-53 to inhibit C5a-induced Ca2+ mobilization in HMC-1 cells and to cause degranulation in RBL-2H3 cells expressing MrgX2[1]. |
| In vivo | Local pretreatment of rats with PMX-53 (60-180?μg per paw) inhibits zymosan-, carrageenan-, lipopolysaccharide (LPS)- and antigen-induced hypernociception[2]. Pharmacokinetic analyses demonstrate that PMX-53 appears in the plasma within 5 min of oral administration (3 mg/kg) to rats, with peak blood levels of approximately 0.3 μM being reached within 20 min. The plasma elimination half-life was approximately 70 min in this case[3]. |
| Molecular Weight | 956.16 |
| Formula | C49H69N11O9 |
| Cas No. | 852629-88-0 |
| Smiles | N=C(N)NCCC[C@@H]1NC([C@H](CC2=CNC3=C2C=CC=C3)NC([C@@H](CC4CCCCC4)NC([C@H]5N(C([C@H](CCCNC1=O)NC([C@H](CC6=CC=CC=C6)NC(C)=O)=O)=O)CCC5)=O)=O)=O.CC(O)=O |
| Relative Density. | no data available |
| Sequence | Ac-Phe-Orn(1)-Pro-D-Cha-Trp-Arg-(1) |
| Sequence Short | FPWR |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 95.6 mg/mL (99.98 mM), Sonication and heating are recommended. DMSO: 125 mg/mL (130.73 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
H2O/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.